Navigation Links
New Migraine Drug Shows Promise
Date:11/24/2008

Telcagepant works differently than standard triptans, researchers say

MONDAY, Nov. 24 (HealthDay News) -- A drug called telcagepant proved safe and effective in treating migraines and caused fewer side effects than the widely-used migraine drug zolmitriptan (Zomig), according to a study conducted by drug maker Merck & Co.

Zolmitriptan and other triptans are effective but can cause a number of side effects, including dizziness, tingling and numbness of the skin, chest discomfort, and throat tightness. In addition, triptans cause blood vessel narrowing and aren't recommended for patients with cardiovascular disease, high blood pressure and certain migraine subtypes, according to a news release about the study.

Telcagepant is from a different class, called calcitonin gene-related peptide (CGRP) antagonists. It's believed that brain concentrations of CGRP are elevated during a migraine. CGRP antagonists don't seem to have blood vessel narrowing properties and, therefore, may not carry the same cardiovascular-related risks as triptans.

This phase III study included 1,380 patients at 81 sites in Europe and the United States. The patients, who suffered from moderate or severe migraines, received either 150 milligrams or 300 milligrams of telcagepant, 5 milligrams zolmitriptan, or a placebo.

The 300-milligram dose of telcagepant was more effective than placebo for freedom from pain (27 percent of patients vs. 10 percent), pain relief (55 percent vs. 28 percent), absences of noise sensitivity (58 percent vs. 37 percent) and light sensitivity (51 percent vs. 29 percent), and nausea (65 percent vs. 55 percent), according to the study.

Telcagepant 300 milligram and zolmitriptan 5 milligram were similarly effective in treating migraines, and both were more effective than telcagepant 150 milligram. Negative side effects were reported by 31 percent of patients taking telcagepant 150 milligram, 32 percent taking placebo, 37 percent taking telcagepant 300 milligram, and 51 percent taking 5 milligram zolmitriptan.

"One potential benefit of the new CGRP receptor antagonist class of acute migraine treatments is the absence of vasoconstriction, a liability of the triptans, which may allow for the safe administration of telcagepant in patients with migraine with cardiovascular disease," the study authors wrote. "However, such patients were excluded from the present study because of the contraindication for zolmitriptan, and further studies are necessary to determine the safety of telcagepant in patients with cardiovascular disease. Additional studies are also necessary to assess the long-term efficacy and safety profile of telcagepant in patients treating more than one migraine attack."

The study was published online Nov. 25 and in an upcoming print issue of The Lancet. Preliminary results from the trial were presented in June at the American Headache Society's annual meeting, in Boston.

"This result marks a new era in migraine therapy. However, the remaining issue is to understand the site of action of the CGRP-receptor antagonists," Dr. Lars Edvinsson, of Lund University in Sweden, wrote in an editorial comment accompanying The Lancet study.

More information

The American Academy of Neurology has more about migraine treatments.



-- Robert Preidt



SOURCE: The Lancet, news release, Nov. 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Neuromuscular Dentistry Ends Womans Migraines
2. Migraine Tied to Thickening in Brain Area
3. Business Coalition Honors BlueChoice HealthPlan for Migraine Program
4. The HealthCentral Network Wins eHealthcare Awards for Breast Cancer and Migraine Web Sites
5. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
6. Comatose locusts may help relieve migraines
7. Epilepsy Drug Doesnt Prevent Migraines
8. MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest
9. Migraines Frequency Influences Heart Attack, Stroke Risk
10. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
11. Skin Pain, Sensitivity Rises With Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Migraine Drug Shows Promise
(Date:3/29/2017)... ... ... During the last week of March, Chad Kawa, MD of Revere Health ... local community. , Colon cancer is the second leading cause of cancer deaths ... is small, confined and easier to treat. If you are 50 or older, colonoscopies ...
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced ... dealer websites for its network of more than 650 U.S.-based dealers. Rhino, a member ... including rotary and flail mowers and cutters, rear blades, post hole diggers, pasture renovators, ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up to 36% ... other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors ... finding more effective treatment options, the San Diego Gamma Knife Center offers ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... professional squash, announced it has enlisted New York City-based sports and entertainment marketing ... develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes ...
(Date:3/29/2017)... ... ... Full Contact K9, an Atlanta-based dog services provider, has recently teamed up ... owners in creating legally-enforceable pet trusts for their canine companions. , Therilus, a ... their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When our clients ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets ... Market Size & Forecast By Type (Insource IONM, Outsource IONM), ... report to their offering. ... The global Intraoperative Neuromonitoring (IONM) market ... intraoperative neuromonitoring market is anticipated to witness significant growth in ...
(Date:3/29/2017)... , March 29, 2017  Bodycad announced today ... Administration (FDA) 510(k) clearance for its Bodycad Unicompartmental ... truly personalized orthopaedic restoration. Bodycad is the first ... joint reconstruction implant system. Bodycad,s ... personalized restoration of the patient,s unique anatomical features ...
(Date:3/29/2017)... , March 29, 2017 Wound care ... promote healing of the wound. The industry mainly consists ... products for the treatment of wounds caused by mechanical, ... due to diseases such as diabetes, skin related diseases, ... Europe was the largest region in ...
Breaking Medicine Technology: